Charles Schwab Investment Management Inc. Increases Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Charles Schwab Investment Management Inc. increased its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 0.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 906,646 shares of the biopharmaceutical company’s stock after buying an additional 1,737 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.86% of Intra-Cellular Therapies worth $75,723,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. True Wealth Design LLC purchased a new stake in shares of Intra-Cellular Therapies during the third quarter valued at $32,000. GAMMA Investing LLC boosted its holdings in Intra-Cellular Therapies by 46.3% in the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 240 shares during the last quarter. Venturi Wealth Management LLC purchased a new stake in Intra-Cellular Therapies in the fourth quarter valued at $96,000. Wilmington Savings Fund Society FSB purchased a new stake in Intra-Cellular Therapies in the third quarter valued at $97,000. Finally, Quarry LP boosted its holdings in Intra-Cellular Therapies by 260.0% in the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock valued at $132,000 after purchasing an additional 1,300 shares during the last quarter. 92.33% of the stock is owned by hedge funds and other institutional investors.

Intra-Cellular Therapies Stock Up 0.0 %

ITCI opened at $131.25 on Tuesday. Intra-Cellular Therapies, Inc. has a twelve month low of $63.30 and a twelve month high of $131.36. The company has a 50-day moving average price of $120.15 and a 200 day moving average price of $94.08. The company has a market cap of $13.96 billion, a PE ratio of -150.86 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. As a group, sell-side analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and upped their price target for the company from $119.00 to $132.00 in a report on Friday, January 31st. StockNews.com assumed coverage on shares of Intra-Cellular Therapies in a report on Tuesday, March 4th. They issued a “hold” rating on the stock. Mizuho lowered shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $140.00 to $132.00 in a report on Monday, February 24th. Finally, Leerink Partnrs lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Ten analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Intra-Cellular Therapies has a consensus rating of “Hold” and a consensus target price of $106.08.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.